Patents by Inventor Neeraj Jagdish Agrawal

Neeraj Jagdish Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240343832
    Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Application
    Filed: April 24, 2024
    Publication date: October 17, 2024
    Applicant: AMGEN INC.
    Inventors: JOON HOI HUH, RIKI STEVENSON, PAVEL BONDARENKO, ANDREW NICHOLS, DA REN, NEERAJ JAGDISH AGRAWAL, RICHARD SMITH
  • Publication number: 20240327486
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: April 5, 2024
    Publication date: October 3, 2024
    Applicant: Amgen Inc.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Randal Robert KETCHEM, Ai Ching LIM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI
  • Patent number: 12103979
    Abstract: Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 1, 2024
    Assignee: Amgen Inc.
    Inventors: Neeraj Jagdish Agrawal, Pavan Ghattyvenkatakrishna, Sekhar Kanapuram, Christopher James Sloey
  • Publication number: 20240301087
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Application
    Filed: March 12, 2024
    Publication date: September 12, 2024
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Campbell Graham, Jennitte LeAnn Stevens, Gregory Moore
  • Patent number: 11993663
    Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: May 28, 2024
    Assignee: AMGEN INC.
    Inventors: Joon Hoi Huh, Riki Stevenson, Pavel Bondarenko, Andrew Nichols, Da Ren, Neeraj Jagdish Agrawal, Richard Smith
  • Publication number: 20240150448
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 9, 2024
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 11976103
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: May 7, 2024
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Randal Robert Ketchem, Ai Ching Lim, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • Patent number: 11891435
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: February 6, 2024
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • Publication number: 20230381276
    Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
    Type: Application
    Filed: December 1, 2022
    Publication date: November 30, 2023
    Applicant: AMGEN INC.
    Inventors: Khaled M.K.Z. ALI, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Ian FOLTZ, Zhulun WANG, Darren BATES, Marissa MOCK, Shunsuke TAKENAKA
  • Publication number: 20230159656
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Application
    Filed: November 10, 2022
    Publication date: May 25, 2023
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens
  • Publication number: 20230048658
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Application
    Filed: May 26, 2022
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Trent P. MUNRO, Neeraj Jagdish AGRAWAL, Kristine M. DARIS
  • Patent number: 11541103
    Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 3, 2023
    Assignee: Amgen Inc.
    Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Darren Bates, Marissa Mock, Shunsuke Takenaka
  • Patent number: 11530274
    Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 20, 2022
    Assignees: AMGEN INC., XENCOR, INC.
    Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
  • Patent number: 11518808
    Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 6, 2022
    Assignee: Amgen Inc.
    Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Daren Bates, Marissa Mock, Shunsuke Takenaka
  • Publication number: 20220363770
    Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 17, 2022
    Applicant: AMGEN INC.
    Inventors: Irwin CHEN, Su CHONG, Fernando GARCES, Mark Leo MICHAELS, Christopher MOHR, Kenneth William WALKER, Zhulun WANG, Neeraj Jagdish AGRAWAL, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Derek E. PIPER, Cen XU
  • Publication number: 20220195022
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Publication number: 20220144920
    Abstract: Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 12, 2022
    Inventors: Jennitte LeAnn STEVENS, Deniz TEMEL, Bram ESTES, Neeraj Jagdish AGRAWAL
  • Patent number: 11248043
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 15, 2022
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • Publication number: 20210371544
    Abstract: The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 2, 2021
    Applicant: AMGEN INC.
    Inventors: JOON HOI HUH, RIKI STEVENSON, PAVEL BONDARENKO, ANDREW NICHOLS, DA REN, NEERAJ JAGDISH AGRAWAL, RICHARD SMITH
  • Patent number: 11059908
    Abstract: The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 13, 2021
    Assignee: AMGEN INC.
    Inventors: Joon Hoi Huh, Riki Stevenson, Pavel Bondarenko, Andrew Nichols, Da Ren, Neeraj Jagdish Agrawal